Imperial College London
Dr Carmel Stock

DrCarmelStock

Faculty of Medicine, National Heart & Lung Institute

Honorary Research Associate
 
 
 
//

Contact

 

c.stock

 
 
//

Location

 

2129Sydney StreetRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{van:2023:10.1111/resp.14440,
author = {van, der Vis JJ and Prasse, A and Renzoni, EA and Stock, CJW and Caliskan, C and Maher, TM and Bonella, F and Borie, R and Crestani, B and Petrek, M and Wuyts, WA and Wind, AE and Molyneaux, PL and Grutters, JC and van, Moorsel CHM},
doi = {10.1111/resp.14440},
journal = {Respirology},
pages = {455--464},
title = {MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis},
url = {http://dx.doi.org/10.1111/resp.14440},
volume = {28},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background and Objective:The minor T-allele of the MUC5B promoter polymorphism rs35705950 is strongly associated with idiopathic pulmonary fibrosis (IPF). However, conflicting results have been reported on the relationship between the MUC5B minor allele and survival and it is unknown whether a specific subgroup of IPF patients might benefit from MUC5B minor allele carriage. We investigated the association between MUC5B rs35705950, survival and patient characteristics in a real-world population of European IPF patients.Methods:In this retrospective study, 1751 patients with IPF from 8 European centres were included. MUC5B rs35705950 genotype, demographics, clinical characteristics at diagnosis and survival data were analysed.Results:In a multi-variate Cox proportional hazard model the MUC5B minor allele was a significant independent predictor of survival when adjusted for age, sex, high resolution computed tomography pattern, smoking behaviour and pulmonary function tests in IPF. MUC5B minor allele carriers were significantly older at diagnosis (p = 0.001). The percentage of MUC5B minor allele carriers increased significantly with age from 44% in patients aged <56 year, to 63% in patients aged >75. In IPF patients aged <56, the MUC5B minor allele was not associated with survival. In IPF patients aged ≥56, survival was significantly better for MUC5B minor allele carriers (45 months [CI: 42–49]) compared to non-carriers (29 months [CI: 26–33]; p = 4 × 10−12).Conclusion:MUC5B minor allele carriage associates with a better median transplant-free survival of 16 months in the European IPF population aged over 56 years. MUC5B genotype status might aid disease prognostication in clinical management of IPF patients.
AU  - van,der Vis JJ
AU  - Prasse,A
AU  - Renzoni,EA
AU  - Stock,CJW
AU  - Caliskan,C
AU  - Maher,TM
AU  - Bonella,F
AU  - Borie,R
AU  - Crestani,B
AU  - Petrek,M
AU  - Wuyts,WA
AU  - Wind,AE
AU  - Molyneaux,PL
AU  - Grutters,JC
AU  - van,Moorsel CHM
DO  - 10.1111/resp.14440
EP  - 464
PY  - 2023///
SN  - 1323-7799
SP  - 455
TI  - MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis
T2  - Respirology
UR  - http://dx.doi.org/10.1111/resp.14440
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000903699500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://onlinelibrary.wiley.com/doi/10.1111/resp.14440
UR  - http://hdl.handle.net/10044/1/102150
VL  - 28
ER  -
Download